Propanc Biopharma, Inc. (Nasdaq: PPCB) announced plans to begin a Phase 1b first-in-human study of its drug candidate PRP in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE